BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 21819259)

  • 1. Breast cancer medications and vision: effects of treatments for early-stage disease.
    Eisner A; Luoh SW
    Curr Eye Res; 2011 Oct; 36(10):867-85. PubMed ID: 21819259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
    Sammons S; Sedrak MS; Kimmick GG
    Drugs Aging; 2020 May; 37(5):331-348. PubMed ID: 32100240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
    Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular effects of aromatase inhibitors: data from clinical trials.
    Howell A; Cuzick J
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinal hemorrhages in anastrozole users.
    Eisner A; Falardeau J; Toomey MD; Vetto JT
    Optom Vis Sci; 2008 May; 85(5):301-8. PubMed ID: 18451730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Adjuvant Tamoxifen Use on Macula Pigment Epithelium Optical Density, Visual Acuity and Retinal Thickness in Patients with Breast Cancer.
    Bicer T; Imamoglu GI; Caliskan S; Bicer BK; Gurdal C
    Curr Eye Res; 2020 May; 45(5):623-628. PubMed ID: 31684771
    [No Abstract]   [Full Text] [Related]  

  • 9. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
    Santen RJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.
    Bender CM; Sereika SM; Brufsky AM; Ryan CM; Vogel VG; Rastogi P; Cohen SM; Casillo FE; Berga SL
    Menopause; 2007; 14(6):995-8. PubMed ID: 17898668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ
    Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in the endocrine management of breast cancer.
    Mouridsen HT; Rose C; Brodie AH; Smith IE
    Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
    Schilder CM; Seynaeve C; Beex LV; Boogerd W; Linn SC; Gundy CM; Huizenga HM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
    J Clin Oncol; 2010 Mar; 28(8):1294-300. PubMed ID: 20142601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women.
    Colozza M; Califano R; Minenza E; Dinh P; Azambuja E
    Mini Rev Med Chem; 2008 Jun; 8(6):564-74. PubMed ID: 18537711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
    Carlson RW; Hudis CA; Pritchard KI; ; ;
    J Natl Compr Canc Netw; 2006 Nov; 4(10):971-9. PubMed ID: 17112447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
    Perez EA
    Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.